Show simple item record

dc.contributor.authorMcAnena, Peter
dc.contributor.authorTanriverdi, Kahraman
dc.contributor.authorCurran, Catherine
dc.contributor.authorGilligan, K.
dc.contributor.authorFreedman, Jane E.
dc.contributor.authorBrown, James A. L.
dc.contributor.authorKerin, Michael J.
dc.date2022-08-11T08:09:53.000
dc.date.accessioned2022-08-23T16:47:16Z
dc.date.available2022-08-23T16:47:16Z
dc.date.issued2019-05-10
dc.date.submitted2019-06-21
dc.identifier.citation<p>BMC Cancer. 2019 May 10;19(1):436. doi: 10.1186/s12885-019-5636-y. <a href="https://doi.org/10.1186/s12885-019-5636-y">Link to article on publisher's site</a></p>
dc.identifier.issn1471-2407 (Linking)
dc.identifier.doi10.1186/s12885-019-5636-y
dc.identifier.pmid31077182
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41048
dc.description.abstractBACKGROUND: Breast cancer is the leading cause of cancer related death in women, with metastasis the principle cause of mortality. New non-invasive prognostic markers are needed for the early detection of metastasis, facilitating treatment decision optimisation. MicroRNA (miRNA) are small, non-coding RNAs regulating gene expression and involved in many cellular processes, including metastasis. As biomarkers, circulating miRNAs (in blood) hold great promise for informing diagnosis or monitoring treatment responses. METHODS: Plasma extracted RNA from age matched local Luminal A (n = 4) or metastatic disease (n = 4) were profiled using Next Generation Sequencing. Selected differentially expressed miRNA were validated on a whole blood extracted miRNA cohort [distant metastatic disease (n = 22), local disease (n = 31), healthy controls (n = 21)]. Area Under the Curve (AUC) in Receiver Operating Characteristic (ROC) analyses was performed. RESULTS: Of 4 miRNA targets tested (miR-181a, miR-329, miR-331, miR-195), mir-331 was significantly over-expressed in patients with metastatic disease, compared to patients with local disease (p < 0.001) or healthy controls (p < 0.001). miR-195 was significantly under-expressed in patients with metastatic disease, compared to patients with local disease (p < 0.001) or healthy controls (p = 0.043). In combination, miR-331 and miR-195 produced an AUC of 0.902, distinguishing metastatic from local breast cancer. CONCLUSIONS: We identified and validated two circulating miRNAs differentiating local Luminal A breast cancers from metastatic breast cancers. Further investigation will reveal the molecular role of these miRNAs in metastasis, and determine if they are subtype specific. This work demonstrates the ability of circulating miRNA to identify metastatic disease, and potentially inform diagnosis or treatment effectiveness.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=31077182&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rights© The Author(s). 2019 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBiomarker
dc.subjectBreast
dc.subjectCancer
dc.subjectMetastasis
dc.subjectmiR-195
dc.subjectmiR-331
dc.subjectmiRNA
dc.subjectBiological Factors
dc.subjectCancer Biology
dc.subjectComputational Biology
dc.subjectDiagnosis
dc.subjectNeoplasms
dc.subjectNucleic Acids, Nucleotides, and Nucleosides
dc.titleCirculating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer
dc.typeJournal Article
dc.source.journaltitleBMC cancer
dc.source.volume19
dc.source.issue1
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4855&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3840
dc.identifier.contextkey14784745
refterms.dateFOA2022-08-23T16:47:17Z
html.description.abstract<p>BACKGROUND: Breast cancer is the leading cause of cancer related death in women, with metastasis the principle cause of mortality. New non-invasive prognostic markers are needed for the early detection of metastasis, facilitating treatment decision optimisation. MicroRNA (miRNA) are small, non-coding RNAs regulating gene expression and involved in many cellular processes, including metastasis. As biomarkers, circulating miRNAs (in blood) hold great promise for informing diagnosis or monitoring treatment responses.</p> <p>METHODS: Plasma extracted RNA from age matched local Luminal A (n = 4) or metastatic disease (n = 4) were profiled using Next Generation Sequencing. Selected differentially expressed miRNA were validated on a whole blood extracted miRNA cohort [distant metastatic disease (n = 22), local disease (n = 31), healthy controls (n = 21)]. Area Under the Curve (AUC) in Receiver Operating Characteristic (ROC) analyses was performed.</p> <p>RESULTS: Of 4 miRNA targets tested (miR-181a, miR-329, miR-331, miR-195), mir-331 was significantly over-expressed in patients with metastatic disease, compared to patients with local disease (p < 0.001) or healthy controls (p < 0.001). miR-195 was significantly under-expressed in patients with metastatic disease, compared to patients with local disease (p < 0.001) or healthy controls (p = 0.043). In combination, miR-331 and miR-195 produced an AUC of 0.902, distinguishing metastatic from local breast cancer.</p> <p>CONCLUSIONS: We identified and validated two circulating miRNAs differentiating local Luminal A breast cancers from metastatic breast cancers. Further investigation will reveal the molecular role of these miRNAs in metastasis, and determine if they are subtype specific. This work demonstrates the ability of circulating miRNA to identify metastatic disease, and potentially inform diagnosis or treatment effectiveness.</p>
dc.identifier.submissionpathoapubs/3840
dc.contributor.departmentUMass Memorial Heart & Vascular Center
dc.contributor.departmentDepartment of Medicine, Division of Cardiovascular Medicine
dc.source.pages436


Files in this item

Thumbnail
Name:
s12885_019_5636_y.pdf
Size:
1.691Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© The Author(s). 2019 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Except where otherwise noted, this item's license is described as © The Author(s). 2019 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.